We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
P03-317 - Reduced risk of hospitalisation with risperidone long-acting injectable. Results of the french cohort for the general study of schizophrenia (CGS)
- Authors
Grimaldi-Bensouda, L.; Rouillon, F.; Astruc, B.; Rossignol, M.; Benichou, J.; Falissard, B.; Thibaut, F.; Limosin, F.; Beaufils, B.; Vaiva, G.; Verdoux, H.; Moride, Y.; Abenhaim, L.; Rasul, F.
- Abstract
Introduction: Medication non-adherence is a significant risk factor for rehospitalisation in schizophrenia patients. Delayed release formulations like R-LAI may reduce rehospitalisation. Objectives: To examine the association between R-LAI use and hospitalisation in schizophrenia patients. Aims: To assess the effect of R-LAI, compared to non-use and use of other antipsychotic drugs, on the risk of hospitalization in real-life settings. Method: The CGS study recruited schizophrenia patients from 177 public and private wards of psychiatric hospitals across France. Inclusion criteria were schizophrenia (DSM-IV), age 15–65 years, ambulatory/hospitalised for < 93 days at entry. Patients were followed up to 12 months for antipsychotic use and hospitalisation. The recruitment was stratified for long-acting second generation antipsychotic use. Multivariate Poisson regression adjusted for confounding with propensity scores and allowing for autocorrelation was used to estimate relative rates of hospitalisation. Results: Of 2092 eligible patients, 1859 were included. Their mean age was 38.1±11.1 years, 68.6% were male and 37.8% were hospitalised for < 93 days at entry. A total of 1659 patients (89.2%) were followed up for 12 months, accumulating 933 hospital stays (53.0 per 100 person-years). Compared to other schizophrenia patients, patients on R-LAI were younger, had more often a history of previous hospitalisation for equivalent severity, living conditions and other characteristics. The adjusted relative rate of hospitalisation for R-LAI use against non-use was 0.66 [95% CI 0.46–0.96], and 0.53 [95% CI 0.32–0.88] against long-acting first generation antipsychotics. Conclusions: Use of R-LAI was associated with lower rates of hospitalization compared to non-use of R-LAI.
- Subjects
FRANCE; SCHIZOPHRENIA treatment; HOSPITAL care; RISPERIDONE; COHORT analysis; ANTIPSYCHOTIC agents
- Publication
European Psychiatry, 2011, Vol 26, p1487
- ISSN
0924-9338
- Publication type
Abstract
- DOI
10.1016/S0924-9338(11)73191-1